CuraTeQ Biologics Pvt Ltd enters into agreement with STADA Arzneimittel AG

CuraTeQ Biologics Pvt Ltd, a wholly owned subsidiary of Aurobindo Pharma Ltd and focused on biosimilars, today announces that it has entered into a marketing and distribution agreement with a leading European healthcare and pharmaceuticals company STADA Arzneimittel AG. Under the terms of the agreement, STADA will market and distribute two EMA approved biosimilars developed by CuraTeQ in select European Union territories, including France and Germany. New brand names will be created and registered for each biosimilar. This agreement is expected to expand CuraTeQ's market reach, drive revenue growth, and leverage STADA's established distribution network in EU markets.

Shares of Aurobindo Pharma Limited was last trading in BSE at Rs. 1307.70 as compared to the previous close of Rs. 1281.25. The total number of shares traded during the day was 1108902 in over 21454 trades.

The stock hit an intraday high of Rs. 1329.95 and intraday low of 1283.00. The net turnover during the day was Rs. 1457258316.00.

Source : Equity Bulls

Keywords

AurobindoPharma INE406A01037 Pharmaceuticals CuraTeQBiologics Biosimilars Marketing Distribution Agreement STADAArzneimittelAG